• circ_0136666 Drives Gastric Cancer via miR-375/PRKDC Axis an

  2026-05-27

  Miao et al. (2023) identify hsa_circ_0136666 as a key driver of gastric cancer progression and immune evasion, acting through the miR-375/PRKDC axis to promote PD-L1 phosphorylation and suppress antitumor immunity. These findings highlight a novel regulatory mechanism and suggest new avenues for improving immunotherapy efficacy in gastric cancer.

• Elastic Hydrogel Microspheres Modulate IVDD via Inflammation

  2026-05-27

  This study presents a dual-network hydrogel microsphere system (PMCCP) for targeted delivery of miR-155 to nucleus pulposus cells, offering a strategy to combat intervertebral disc degeneration (IVDD) by modulating inflammation and inhibiting apoptosis. The robust design addresses key challenges in miRNA therapeutic delivery, showing efficacy in both in vitro and in vivo IVDD models.

• β-Amanitin in RNA Polymerase II Research: Applied Workflows

  2026-05-26

  β-Amanitin stands as a gold-standard tool for RNA polymerase II transcription studies and mRNA synthesis inhibition assays. This article delivers actionable experimental workflows, advanced troubleshooting, and strategic insights drawn from cutting-edge computational and immunodetection advances—empowering researchers to leverage APExBIO’s high-purity β-Amanitin for both molecular biology and toxicology innovation.

• Optimizing Storage for LNP-Formulated Self-Replicating mRNA

  2026-05-26

  This study systematically investigates how storage conditions affect the stability and potency of lipid nanoparticle (LNP)-formulated self-replicating RNA vaccines. The findings inform best practices for preserving mRNA vaccine bioactivity, directly impacting translational workflows for mRNA therapeutics.

• LNP-Delivered NamiRNA Suppresses Pancreatic Cancer via Dual

  2026-05-25

  Yu et al. (2025) demonstrate that lipid nanoparticle (LNP)-enclosed miR-200c acts as a nuclear activating miRNA (NamiRNA) to inhibit pancreatic cancer cell proliferation and migration through both transcriptional activation and post-transcriptional repression. These findings highlight the therapeutic promise of NamiRNA-based strategies and offer new avenues for translational cancer research.

• Cimetidine’s Distinct Role in H2R Signaling and Translationa

  2026-05-25

  This article explores Cimetidine’s unique pharmacological attributes as a histamine-2 receptor antagonist with partial agonist activity, focusing on its mechanistic underpinnings, experimental validation in cancer and blood-brain barrier (BBB) models, and the translational guidance it provides for optimizing preclinical workflows. Drawing on recent high-throughput BBB modeling advances, we dissect how APExBIO’s high-purity Cimetidine empowers researchers to address experimental complexities not met by traditional H2 antagonists.

• Nicotinamide Riboside Chloride (NIAGEN): Reliable NAD+ Boost

  2026-05-24

  This article offers a scenario-driven, evidence-based guide for using Nicotinamide Riboside Chloride (NIAGEN, SKU C7038) to address common challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed data and validated protocols, it demonstrates how this NAD+ precursor can enhance reproducibility and sensitivity in metabolic and neurodegenerative disease research workflows.

• Aconitase Activity Colorimetric Assay Kit: Reliable TCA Cycl

  2026-05-23

  This article addresses common laboratory challenges in measuring mitochondrial aconitase activity and oxidative damage, highlighting the advantages of the Aconitase Activity Colorimetric Assay Kit (SKU K2226) for reproducible, high-sensitivity detection. Scenario-based Q&A explores real-world issues in assay design, data interpretation, workflow optimization, and vendor reliability—grounded in peer-reviewed evidence and validated protocols.

• NU7441 (KU-57788): Precision DNA-PK Inhibition for DNA Repai

  2026-05-22

  Explore how NU7441 (KU-57788), a highly selective DNA-PK inhibitor, is shaping DNA repair and oncology research. This article uniquely connects mechanistic insights to practical assay strategies and HIV latency research.

• AO/PI Staining Solution: Precision in Fluorescent Cell Viabi

  2026-05-22

  AO/PI Staining Solution empowers researchers to achieve high-fidelity live/dead cell discrimination in complex settings like diabetic nephropathy models. Its dual fluorescent DNA dye mechanism outperforms traditional stains, enabling robust membrane integrity assays and reproducible cell counting, even amidst inflammation-driven apoptosis.

• HIV-1 Latency Increases DNA Damage Susceptibility in Brain P

  2026-05-21

  This study reveals that HIV-1 infection impairs the DNA damage response in brain vascular pericytes, rendering them more susceptible to extracellular glutamate and inflammatory stimuli. These findings provide mechanistic insight into how HIV-associated neuroinflammation compromises blood-brain barrier integrity and point to new experimental models for DNA repair research.

• Pharmacokinetic Variability of CSBTA in MASH: Mechanistic In

  2026-05-21

  This study elucidates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in high-fat, high-cholesterol diet mice. The findings reveal that disease-induced modulation of drug-metabolizing enzymes and transporters drives significant variability in systemic and hepatic exposure, providing a foundation for more rational therapeutic strategies in MASLD/MASH.

• TH287 MTH1 Inhibitor: Enabling Selective Radiosensitization

  2026-05-20

  TH287, a potent MTH1 inhibitor, unlocks targeted radiosensitization for resistant cancer cell models through precise manipulation of oxidative DNA damage. This guide delivers actionable protocols, troubleshooting intelligence, and a translation of the latest research for researchers leveraging TH287 in cancer biology.

• Live-Dead Cell Staining Kit: Precision Cell Viability Assays

  2026-05-20

  The Live-Dead Cell Staining Kit empowers researchers to distinguish viable from non-viable cells with superior accuracy using Calcein-AM and Propidium Iodide dual staining. Its versatility across flow cytometry, fluorescence microscopy, and cytotoxicity testing makes it the benchmark for robust, reproducible cell viability data.

• T7 RNA Polymerase in Precision CRISPR and RNA Therapeutics

  2026-05-19

  Explore T7 RNA Polymerase—a recombinant enzyme expressed in E. coli—at the heart of next-generation CRISPR guide RNA production, RNA vaccine synthesis, and cancer gene-editing workflows. Discover practical protocol insights and unique assay considerations that set this article apart from standard overviews.

15644 records 1/1043 page Next 12345 下5页 Last page